Your browser doesn't support javascript.
loading
A Polygenic Risk Score for Idiopathic Pulmonary Fibrosis and Interstitial Lung Abnormalities.
Moll, Matthew; Peljto, Anna L; Kim, John S; Xu, Hanfei; Debban, Catherine L; Chen, Xianfeng; Menon, Aravind; Putman, Rachel K; Ghosh, Auyon J; Saferali, Aabida; Nishino, Mizuki; Hatabu, Hiroto; Hobbs, Brian D; Hecker, Julian; McDermott, Gregory; Sparks, Jeffrey A; Wain, Louise V; Allen, Richard J; Tobin, Martin D; Raby, Benjamin A; Chun, Sung; Silverman, Edwin K; Zamora, Ana C; Ortega, Victor E; Garcia, Christine K; Barr, R Graham; Bleecker, Eugene R; Meyers, Deborah A; Kaner, Robert J; Rich, Stephen S; Manichaikul, Ani; Rotter, Jerome I; Dupuis, Josée; O'Connor, George T; Fingerlin, Tasha E; Hunninghake, Gary M; Schwartz, David A; Cho, Michael H.
Afiliação
  • Moll M; Division of Pulmonary and Critical Care Medicine, and.
  • Peljto AL; Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Kim JS; Department of Medicine and.
  • Xu H; Department of Immunology, Division of Pulmonary Medicine, University of Colorado, Aurora, Colorado.
  • Debban CL; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Virginia, Charlottesville, Virginia.
  • Chen X; Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.
  • Menon A; Center for Public Health Genomics, University of Virginia School of Medicine, Charlottesville, Virginia.
  • Putman RK; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Phoenix, Arizona.
  • Ghosh AJ; Division of Pulmonary and Critical Care Medicine, and.
  • Saferali A; Division of Pulmonary and Critical Care Medicine, and.
  • Nishino M; Department of Medicine, Division of Pulmonary and Critical Care Medicine, State University of New York Upstate Medical Center, Syracuse, New York.
  • Hatabu H; Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Hobbs BD; Center for Pulmonary Functional Imaging, Department of Radiology.
  • Hecker J; Center for Pulmonary Functional Imaging, Department of Radiology.
  • McDermott G; Division of Pulmonary and Critical Care Medicine, and.
  • Sparks JA; Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Wain LV; Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Allen RJ; Division of Rheumatology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • Tobin MD; Division of Rheumatology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • Raby BA; Department of Health Sciences, University of Leicester, Leicester, United Kingdom.
  • Chun S; National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom.
  • Silverman EK; Department of Health Sciences, University of Leicester, Leicester, United Kingdom.
  • Zamora AC; National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom.
  • Ortega VE; Department of Health Sciences, University of Leicester, Leicester, United Kingdom.
  • Garcia CK; National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom.
  • Barr RG; Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Bleecker ER; Department of Pediatrics.
  • Meyers DA; Division of Pulmonary Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Kaner RJ; Division of Pulmonary Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Rich SS; Division of Pulmonary and Critical Care Medicine, and.
  • Manichaikul A; Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Rotter JI; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Phoenix, Arizona.
  • Dupuis J; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Phoenix, Arizona.
  • O'Connor GT; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
  • Fingerlin TE; Department of Medicine and.
  • Hunninghake GM; Division of General Medicine, Department of Epidemiology, Columbia University Medical Center, New York, New York.
  • Schwartz DA; Division of Genetics, Genomics, and Precision Medicine, Department of Medicine, University of Arizona, Tucson, Arizona.
  • Cho MH; Division of Genetics, Genomics, and Precision Medicine, Department of Medicine, University of Arizona, Tucson, Arizona.
Am J Respir Crit Care Med ; 208(7): 791-801, 2023 10 01.
Article em En | MEDLINE | ID: mdl-37523715
ABSTRACT
Rationale In addition to rare genetic variants and the MUC5B locus, common genetic variants contribute to idiopathic pulmonary fibrosis (IPF) risk. The predictive power of common variants outside the MUC5B locus for IPF and interstitial lung abnormalities (ILAs) is unknown.

Objectives:

We tested the predictive value of IPF polygenic risk scores (PRSs) with and without the MUC5B region on IPF, ILA, and ILA progression.

Methods:

We developed PRSs that included (PRS-M5B) and excluded (PRS-NO-M5B) the MUC5B region (500-kb window around rs35705950-T) using an IPF genome-wide association study. We assessed PRS associations with area under the receiver operating characteristic curve (AUC) metrics for IPF, ILA, and ILA progression. Measurements and Main

Results:

We included 14,650 participants (1,970 IPF; 1,068 ILA) from six multi-ancestry population-based and case-control cohorts. In cases excluded from genome-wide association study, the PRS-M5B (odds ratio [OR] per SD of the score, 3.1; P = 7.1 × 10-95) and PRS-NO-M5B (OR per SD, 2.8; P = 2.5 × 10-87) were associated with IPF. Participants in the top PRS-NO-M5B quintile had ∼sevenfold odds for IPF compared with those in the first quintile. A clinical model predicted IPF (AUC, 0.61); rs35705950-T and PRS-NO-M5B demonstrated higher AUCs (0.73 and 0.7, respectively), and adding both genetic predictors to a clinical model yielded the highest performance (AUC, 0.81). The PRS-NO-M5B was associated with ILA (OR, 1.25) and ILA progression (OR, 1.16) in European ancestry participants.

Conclusions:

A common genetic variant risk score complements the MUC5B variant to identify individuals at high risk of interstitial lung abnormalities and pulmonary fibrosis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrose Pulmonar Idiopática / Estudo de Associação Genômica Ampla Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrose Pulmonar Idiopática / Estudo de Associação Genômica Ampla Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article